| DB ID | MyCo_3222 |
| Title | Utility of measuring (1,3)-β-d-glucan in cerebrospinal fluid for diagnosis of fungal central nervous system infection |
| Year | 2014 |
| PMID | 25378578 |
| Fungal Diseases involved | Fungal Central Nervous System infection |
| Disease | Aspergillosis (Aspergillus Infection) |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The research protocol approved by Johns Hopkins Institutional Review Board. |
| Site of Infection | Unspecified |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Cerebrospinal fluid (CSF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | BDG |
| Biomarker Full Name | 1-3-beta-D-Glucan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | Here selected CSF and serum samples collected for routine care between 2007 and 2013 and frozen as part of a research protocol approved by Johns Hopkins Institutional Review Board. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| Fold Change | 25 fold |
| Pathway | None |
| Disease Introduction Mechanism | None |
| Sub Technique | Chemiluminescence |
| Technique | Immunoassay |
| Analysis Method | FDA Approved-Fungitell assay |
| ELISA kits | None |
| Assay Data | FDA- Fungitell®, Cape Cod International, Inc.; Falmounth, MA, USA |
| Validation Techniques used | FDA Approved-Fungitell assay |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
